NTRK1 and hepatocellular carcinoma: In recent years, breakthroughs in gene‐related research and technology have led to the emergence of targeted drugs for HCC, such as multi‐kinase inhibitors sorafenib and tyrosine kinase receptor inhibitors lenvatinib.16